Cargando…
Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth
Loss or dysfunction of tumor suppressor retinoblastoma (RB) is a common feature in various tumors, and contributes to cancer cell stemness and drug resistance to cancer therapy. However, the strategy to suppress or eliminate Rb-deficient tumor cells remains unclear. In the present study, we accident...
Autores principales: | Li, Juan, Liu, Jie, Liang, Zheyong, He, Fang, Yang, Lu, Li, Pingping, Jiang, Yina, Wang, Bo, Zhou, Can, Wang, Yaochun, Ren, Yu, Yang, Jin, Zhang, Jianmin, Luo, Zhijun, Vaziri, Cyrus, Liu, Peijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386551/ https://www.ncbi.nlm.nih.gov/pubmed/28300827 http://dx.doi.org/10.1038/cddis.2017.46 |
Ejemplares similares
-
Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells
por: Liang, Zheyong, et al.
Publicado: (2017) -
DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells
por: Song, Shaoran, et al.
Publicado: (2022) -
Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway
por: Liu, Jie, et al.
Publicado: (2017) -
Origin Licensing Requires ATP Binding and Hydrolysis by the MCM Replicative Helicase
por: Coster, Gideon, et al.
Publicado: (2014) -
MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma
por: Qu, Kai, et al.
Publicado: (2017)